centrosomal protein 295Genealiases: KIAA1731 · SCKL11
Q-omics provides the consensus-scored CEP295 profile across patient tissues and cancer cell-line models. CEP295 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CEP295 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CEP295 RNA expression shows 21,469 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where CEP295 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP295 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP295 survival associations across molecular data types. CEP295 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP295 RNA expression–survival associations across cancer types. High CEP295 expression shows unfavorable associations in ACC, KICH, LIHC and PAAD, but favorable associations in KIRC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CEP295 RNA expression.
This table summarizes CEP295 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CEP295. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP295 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, LUAD and CHOL. The HNSC box plot shows higher CEP295 RNA expression in tumor versus normal tissue (log2 FC = +0.678, t-test p < 0.001).
This table shows molecular features associated with CEP295 in patient tissues and cancer cell lines. In patient samples, CEP295 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP295 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
